Wilmington, DE -- (SBWIRE) -- 09/11/2013 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Ventrus Biosciences Inc. (NASDAQ:VTUS) and Theravance Inc. (NASDAQ:THRX).
Ventrus Biosciences Inc. (NASDAQ:VTUS) a development stage specialty pharmaceutical company that focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders is currently up (+27.91%) on 5,429,421 shares traded after VENTRUS BIOSCIENCES INC Filed SEC form 8-K, Other Events, Financial Statements and Exhibits. Ventrus Biosciences Inc. (NASDAQ:VTUS) is currently up (+80.63%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.
Click Here to find out what other Investors are saying about Ventrus Biosciences Inc. (NASDAQ:VTUS)
Theravance Inc. (NASDAQ:THRX) a biopharmaceutical company that engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system/pain is currently up (+2.94%) on 935,452 shares traded after THERAVANCE INC Filed SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits. Theravance Inc. (NASDAQ:THRX) is currently up (+100.2%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.
Click Here to find out what other Investors are saying about Theravance Inc. (NASDAQ:THRX)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)